The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Commentary|Articles|June 8, 2026
Hematologists Highlight Top Data From ASCO 2026
Author(s)Chris Ryan
Fact checked by: Ashling Wahner , Tracy Ann Politowicz
Experts highlight some top hematologic oncology data presented at ASCO 2026, including from key studies in multiple myeloma and diffuse large B-cell lymphoma.
Advertisement
Advertisement
Key hematologic oncology data drew attention at the
Related to this article
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.
Elranatamab improved PFS vs 3 standard regimens in relapsed/refractory multiple myeloma in the phase 3 MagnetisMM-32 trial.
The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.
The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.
MajesTEC-9 data supported an EU indication expansion for teclistamab in relapsed/refractory multiple myeloma.
Gastrointestinal oncologists weigh HER2 testing practices, the order of HER2-directed therapies, and emerging agents for metastatic colorectal cancer.
Advertisement
Advertisement